Rare Disease Report

Venetoclax and Relapsed/Refractory Chronic Lymphocytic Lymphoma

DECEMBER 11, 2016
Jeffrey Jones, MD, MPH

Jeffrey Jones, MD, MPH of Ohio State University talks about the safety and efficacy of venetoclax monotherapy in patients with relapsed or refractory CLL.


Jones J, Choi MY, Mato AR, et al. Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib. Presented at 58th Annual ASH Meeting & Exposition; San Diego, CA; December 3-6, 2016

Stay informed on the latest rare disease news and developments by signing up for our newsletter.
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.